Joyce O’Shaughnessy, MD

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.